Roche says Avastin approved in EU for type of ovarian cancer
ZURICH (Reuters) - Roche said on Wednesday that European regulators approved its drug Avastin as a treatment for women with ovarian cancer that is resistant to platinum-containing chemotherapy. (Source: Reuters: Health)
Source: Reuters: Health - August 6, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

EU approves Roche's Avastin for platinum-resistant recurrent ovarian cancer
Roche announced today that the European Commission (EU) approved the use of Avastin (bevacizumab) in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin chemotherapy as a treatment for women with recurrent ovarian cancer that is resistant to platinum-containing chemotherapy. (Source: Roche Media News)
Source: Roche Media News - August 6, 2014 Category: Pharmaceuticals Source Type: news

EU approves Roche's Avastin for platinum-resistant recurrent ovarian cancer
Roche announced today that the European Commission (EU) approved the use of Avastin (bevacizumab) in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin chemotherapy as a treatment for women with recurrent ovarian cancer that is resistant to platinum-containing chemotherapy. (Source: Roche Investor Update)
Source: Roche Investor Update - August 6, 2014 Category: Pharmaceuticals Source Type: news

More Safety Data Needed for Intravitreal Anti-VEGF AgentsMore Safety Data Needed for Intravitreal Anti-VEGF Agents
Intravitreal use of bevacizumab and ranibizumab does not appear to cause major cardiovascular events or non-ocular bleeding in patients with eye disease, according to a meta-analysis from France. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 5, 2014 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

FDA grants Roche's Avastin Priority Review for recurrent platinum-resistant ovarian cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for Avastin (bevacizumab) plus chemotherapy for the treatment of women with recurrent platinum-resistant ovarian cancer. (Source: Roche Investor Update)
Source: Roche Investor Update - July 22, 2014 Category: Pharmaceuticals Source Type: news

Immunotherapy for Kidney Cancer
Joseph I. Clark, MD Immunotherapy, a type of treatment designed to enhance or restore the body’s ability to fight cancerous cells by activating the immune system, has long been a mainstay of treatment for kidney cancer, and continues to attract considerable attention from oncologists and patients alike. The attention is not only due to the clinical benefits that patients continue to experience with immunotherapy, but also to the apparent promise of newer immunotherapeutic agents that are currently being investigated in clinical trials. Although surgical resection (removal) of the kidney is often used in patient...
Source: Kidney Cancer Association - July 19, 2014 Category: Cancer & Oncology Source Type: news

Immunotherapy for Kidney Cancer
Joseph I. Clark, MD Immunotherapy, a type of treatment designed to enhance or restore the body’s ability to fight cancerous cells by activating the immune system, has long been a mainstay of treatment for kidney cancer, and continues to attract considerable attention from oncologists and patients alike. The attention is not only due to the clinical benefits that patients continue to experience with immunotherapy, but also to the apparent promise of newer immunotherapeutic agents that are currently being investigated in clinical trials. Although surgical resection (removal) of the kidney is often used in patients wi...
Source: Kidney Cancer Association - July 19, 2014 Category: Urology & Nephrology Source Type: news

Immunotherapy for Kidney Cancer
Joseph I. Clark, MDImmunotherapy, a type of treatment designed to enhance or restore the body’s ability to fight cancerous cells by activating the immune system, has long been a mainstay of treatment for kidney cancer, and continues to attract considerable attention from oncologists and patients alike. The attention is not only due to the clinical benefits that patients continue to experience with immunotherapy, but also to the apparent promise of newer immunotherapeutic agents that are currently being investigated in clinical trials.Although surgical resection (removal) of the kidney is often used in patients with l...
Source: Kidney Cancer Association - July 19, 2014 Category: Urology & Nephrology Source Type: news

FDA grants priority review for Genentech’s cervical cancer therapy
The US Food and Drug Administration (FDA) has accepted Roche subsidiary Genentech's supplemental biologics licence application (sBLA) and granted priority review for Avastin plus chemotherapy for treatment of women with persistent, recurrent or metas… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 16, 2014 Category: Pharmaceuticals Source Type: news

Roche's Avastin In U.S. Priority Review
U.S. health regulators have granted Roche's cancer drug Avastin priority review when used with chemotherapy to treat some types of cervical cancer, the Swiss drug firm said. (Source: WSJ.com: Health)
Source: WSJ.com: Health - July 15, 2014 Category: Pharmaceuticals Tags: PAID Source Type: news

Roche says wins priority review for Avastin in cervical cancer
ZURICH (Reuters) - Swiss drugmaker Roche said U.S. health regulators have granted a priority review of its Avastin drug when combined with chemotherapy to treat women with cervical cancer. (Source: Reuters: Health)
Source: Reuters: Health - July 15, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

FDA grants Roche's Avastin Priority Review for certain types of cervical cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for Avastin (bevacizumab) plus chemotherapy for the treatment of women with persistent, recurrent or metastatic cervical cancer. (Source: Roche Investor Update)
Source: Roche Investor Update - July 15, 2014 Category: Pharmaceuticals Source Type: news

France Says Avastin Is Viable, Less Expensive Alternative Treatment for AMD
In a 272 to 234 vote on Tuesday, French lawmakers amended its social security budget bill to support the use of Roche's cancer drug Avastin as an inexpensive treatment for the eye disease wet age-related macular degeneration (AMD). However, this move has raised some eyebrows; drug makers and medical experts believe that allowing this medication (currently unapproved as an AMD treatment) to be used as such could pose a risk to patients’ health and to the profits of Novartis and Bayer, which currently market AMD drugs. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - July 10, 2014 Category: Pharmaceuticals Source Type: news

France to back Roche cancer drug as cheaper eye treatment
PARIS (Reuters) - The French government, looking to cut healthcare costs, plans to authorize the use of Roche cancer drug Avastin as an alternative eye disease treatment to the much pricier Lucentis, marketed by both Roche and Novartis. (Source: Reuters: Health)
Source: Reuters: Health - July 2, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

Cetuximab or bevacizumab with combi chemo equivalent in KRAS wild-type MCRC
For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 29, 2014 Category: Science Source Type: news

Cetuximab or bevacizumab with combi chemo equivalent in KRAS wild-type MCRC
(European Society for Medical Oncology) For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 28, 2014 Category: Biology Source Type: news

EU Okays Bevacizumab in Ovarian Cancer, Regorafenib in GISTEU Okays Bevacizumab in Ovarian Cancer, Regorafenib in GIST
Another use in a ovarian cancer is recommended for approval in Europe, as is use of regorafenib for gastrointestinal stromal tumors (GIST). International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 28, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Bevacizumab-Pemetrexed for Advanced Nonsquamous NSCLCBevacizumab-Pemetrexed for Advanced Nonsquamous NSCLC
Learn more about the safety and efficacy of bevacizumab maintenance with or without pemetrexed in nonsquamous nonsmall-cell lung cancer. Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 27, 2014 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

EU agency recommends Roche drug for type of ovarian cancer
ZURICH (Reuters) - Roche said on Friday that European regulators had recommended approval of its drug Avastin as a treatment for women with ovarian cancer that is resistant to platinum-containing chemotherapy. (Source: Reuters: Health)
Source: Reuters: Health - June 27, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

CHMP recommends EU approval of Roche's Avastin for platinum-resistant recurrent ovarian cancer
Roche announced today that the EU Committee for Medicinal Products for Human Use (CHMP) recommended that the European Commission approve the use of Avastin (bevacizumab) in combination with chemotherapy as a treatment for women with ovarian cancer that is resistant to platinum-containing chemotherapy. Ovarian cancer has the highest mortality rate of all gynaecological cancers.1 Of the 230,000 women diagnosed worldwide each year many will have advanced disease that will return after initial treatment. (Source: Roche Media News)
Source: Roche Media News - June 27, 2014 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche's Avastin for platinum-resistant recurrent ovarian cancer
Roche announced today that the EU Committee for Medicinal Products for Human Use (CHMP) recommended that the European Commission approve the use of Avastin (bevacizumab) in combination with chemotherapy as a treatment for women with ovarian cancer that is resistant to platinum-containing chemotherapy. Ovarian cancer has the highest mortality rate of all gynaecological cancers.1 Of the 230,000 women diagnosed worldwide each year many will have advanced disease that will return after initial treatment. (Source: Roche Investor Update)
Source: Roche Investor Update - June 27, 2014 Category: Pharmaceuticals Source Type: news

Switch From Lucentis to Avastin Could Save Medicare $18BSwitch From Lucentis to Avastin Could Save Medicare $18B
Medicare could slash $18 billion in spending over the course of 10 years if physicians treated patients with vision-robbing ailments with bevacizumab instead of ranibizumab. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 17, 2014 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Combo Scores High in Ovarian Cancer, for NowCombo Scores High in Ovarian Cancer, for Now
Drs. Stanley Kaye and Robert Coleman highlight the gynecologic presentations of ASCO 2014, including a positive PARP combination trial, early results for immunotherapy, and a test for bevacizumab use. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 16, 2014 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Wet AMD drug changed by Italy government
Dr Steven Bradshaw, a drug policy expert and former ophthalmologist, is disappointed at the news of the Italian government’s decision to substitute wet age-related macular degeneration treatment drug, from Lucentis to Roche’s Avastin. (Source: Pharmacy Europe)
Source: Pharmacy Europe - June 16, 2014 Category: Drugs & Pharmacology Authors: AMcculloch Tags: Industry News avastin italy Latest News lucentis Steven Bradshaw wet age-related macular degeneration Source Type: news

Adding Bevacizumab Ineffective in AngiosarcomaAdding Bevacizumab Ineffective in Angiosarcoma
Bevacizumab plus weekly paclitaxel did not improve outcomes in advanced angiosarcoma. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 16, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Colon Cancer Alliance - high out-of-pocket costs
The Colon Cancer Alliance is committed to providing support and empowerment to those who are affected by colon cancer. This is why we’re actively addressing the patient impact of high out-of-pocket costs for medicine.  Due to increased costs, patients are making decisions about treatment based on financial implication as opposed to selecting the best treatment path to address their current condition.  The Affordable Care Act and Health Insurance Exchanges were intended to address the need for affordable care. The new Avelere study supports the patient stories we often hear. High copays and deductibles can c...
Source: PHRMA - June 13, 2014 Category: Pharmaceuticals Authors: Sabrina Source Type: news

Study Finds Selecting Cheaper Eye Drug Could Save U.S. Billions
Researchers at the University of Michigan have found that if eye doctors began to prescribe a less expensive eye drug for the wet form of macular degeneration or those who have diabetic macular edema, the U.S. Medicare system could save as much as $18 billion over 10 years. Patients suffering from these two conditions currently have two treatment options: bevacizumab (branded as Avastin), which costs $55 per treatment, or ranibizumab (branded as Lucentis) which costs $2,023 per treatment. Ranibizumab is almost 40 times more expensive than bevacizumab, and the researchers found that the drugs are very similar in terms of ef...
Source: Pharmaceutical Online News - June 9, 2014 Category: Pharmaceuticals Source Type: news

Test IDs Ovarian Cancers in Which bevacizumab Is No GoodTest IDs Ovarian Cancers in Which bevacizumab Is No Good
A new gene expression test identified high-grade serous ovarian cancer (HGSOC) patients who did well after standard chemotherapy -- and who did worse if bevacizumab was added. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 7, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

ASCO: Targeted Tx Combo Stalls NSCLC
CHICAGO (MedPage Today) -- Adding bevacizumab (Avastin) to first-line targeted therapy delayed progression in a subgroup of non-small cell lung cancer (NSCLC), an open-label trial showed. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - June 3, 2014 Category: Primary Care Source Type: news

The combination of Roche's Avastin and Tarceva helped people with a specific form of lung cancer live longer without their disease worsening
Phase II study in Japanese patients with a specific type of lung cancer meets primary endpoint of improved progression-free survival with the combination of Avastin and Tarceva compared to Tarceva alone. Roche today announced results from the phase II JO25567 study in which Avastin® (bevacizumab) was added to Tarceva® (erlotinib) as initial (first-line) treatment for people with advanced non-small cell lung cancer (NSCLC) characterised by activating mutations of the epidermal growth factor receptor (EGFR Mut+). Patients who received the combination in this study lived significantly longer without their disease gett...
Source: Roche Investor Update - June 2, 2014 Category: Pharmaceuticals Source Type: news

ASCO: Biologic Agents Plus Chemo Equal in Colon Ca
CHICAGO (MedPage Today) -- Treatment with either cetuximab or bevacizumab and standard chemotherapy produced a median survival of about 2.5 years among patients with advanced metastatic colorectal cancer, according to results of a long-term clinical trial. (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - June 1, 2014 Category: Journals (General) Source Type: news

ASCO: Chemo Plus Avastin or Erbitux Boosts Colorectal Ca Survival
CHICAGO (MedPage Today) -- Treatment with either cetuximab or bevacizumab and standard chemotherapy produced a median survival of about 2.5 years among patients with advanced metastatic colorectal cancer, according to results of a long-term clinical trial. (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - June 1, 2014 Category: Journals (General) Source Type: news

Bevacizumab, Cetuximab Have Similar Survival Benefits in CRCBevacizumab, Cetuximab Have Similar Survival Benefits in CRC
Adding either bevacizumab or cetuximab to chemotherapy yielded equal benefits in metastatic colorectal cancer (CRC). Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 1, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Mayo Clinic: Ovarian cancer subtypes may predict response to bevacizumab
(Mayo Clinic) Molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found. Results of the research were presented today at the 2014 American Society of Clinical Oncology Annual Meeting. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 1, 2014 Category: Cancer & Oncology Source Type: news

Eli Lilly Lung Cancer Drug May Succeed Where Avastin Failed
Roche's Avastin is a cancer monolith that generates more than $6 billion in annual sales. But it never worked in squamous cell lung cancer, a form that starts in the lining of the respiratory tract and afflicts a quarter of patients. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - May 31, 2014 Category: Pharmaceuticals Authors: Matthew Herper Source Type: news

Mayo Clinic: Ovarian Cancer Subtypes May Predict Response to Bevacizumab
CHICAGO — Molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found. Results of the research were presented today at the 2014 American Society of Clinical Oncology Annual Meeting. The addition of bevacizumab to standard therapy extended progression-free survival more for [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - May 30, 2014 Category: Databases & Libraries Source Type: news

Europe Says No to Bevacizumab (Avastin) for GlioblastomaEurope Says No to Bevacizumab (Avastin) for Glioblastoma
The European authorities have recommended against approval for an extended indication for bevacizumab for glioblastoma. International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 23, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Bevacizumab for Platinum-Resistant Ovarian CancerBevacizumab for Platinum-Resistant Ovarian Cancer
Adding bevacizumab to standard chemotherapy prolongs survival and eases symptoms in platinum-resistant ovarian cancer. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 3, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Cost of Treatment May Influence Doctors
The American College of Cardiology and the American Heart Association said they would use cost data to rate the value of treatments. (Source: NYT)
Source: NYT - April 18, 2014 Category: American Health Authors: By ANDREW POLLACK Tags: Lucentis (Drug) Gilead Sciences Inc GILD NASDAQ JPMorgan Chase & Company JPM NYSE Drugs (Pharmaceuticals) American Heart Assn American Society of Clinical Oncology Health Insurance and Managed Care Avastin (Drug) American College of Ca Source Type: news

Fluorescein Angiography Details Vasculature in ROPFluorescein Angiography Details Vasculature in ROP
The imaging procedure demonstrates subtle changes in vasculature in bevacizumab-treated eyes with retinopathy of prematurity (ROP), but must be performed by a skilled photographer for optimal results. Medscape Medical News (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - April 8, 2014 Category: Opthalmology Tags: Ophthalmology News Source Type: news

Tocagen Names Jamey Skillings, M.D., Chief Medical Officer
Pharmaceutical Executive Brings Additional Expertise in Oncology Drug Development and Commercialization Oversaw Approvals of Numerous Oncology Products, including Avastin®, Xalkori® and Erbitux® SAN DIEGO, March 25, 2014 -- (Healthcare Sa... Biopharmaceuticals, Oncology, PersonnelTocagen, immunotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 25, 2014 Category: Pharmaceuticals Source Type: news

Cortice starts first stage of Phase II TPI 287-Avastin combination trial to treat glioblastoma
US-based clinical-stage drug development firm Cortice Biosciences has started the first stage of an open-label Phase II trial designed to assess the safety and efficacy of its lead drug candidate, TPI 287, in combination with standard-of-care Avastin… (Source: Drug Development Technology)
Source: Drug Development Technology - March 21, 2014 Category: Pharmaceuticals Source Type: news

UPDATE -- OXiGENE Announces Positive Topline Results From Randomized Phase 2 Study GOG186I of ZYBRESTAT(R) in Combination With Avastin(R) for Recurrent Ovarian Cancer
(Source: Medical News (via PRIMEZONE))
Source: Medical News (via PRIMEZONE) - March 12, 2014 Category: Pharmaceuticals Source Type: news

Oxigene Inc says drug meets main goal of ovarian cancer trial
(Reuters) - Oxigene Inc said on Tuesday that its experimental drug Zybrestat combined with Roche's big selling cancer drug Avastin significantly slowed progression of recurrent ovarian cancer better than Avastin alone in a midstage clinical trial. (Source: Reuters: Health)
Source: Reuters: Health - March 11, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

Novartis And Roche Fined $251 Million By Italian Government
The Italian government fined drug industry giants Novartis and Roche $251 million dollars for their roles in a collusion plot to prevent Roche’s Avastin cancer drug from being used as a treatment for a disease affecting aging eyes. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - March 7, 2014 Category: Pharmaceuticals Source Type: news

Italian Watchdog Says Novartis, Roche Colluded Over Eye DrugItalian Watchdog Says Novartis, Roche Colluded Over Eye Drug
Italy's antitrust authorities said Novartis and Roche colluded to try to stop cancer drug Avastin (bevacizumab) from being used to treat a serious eye disease, and fined the Swiss drugmakers 182.5 million euros ($251 million). Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - March 7, 2014 Category: Opthalmology Tags: Ophthalmology News Source Type: news

Novartis, Roche Face $251M in Collusion Fines
Italian antitrust authorities have fined Novartis and Roche Holdings a total of $250 million for allegedly colluding to prevent the use of Roche’s Avastin cancer drug as a treatment for eye disease, in favor of a more expensive drug. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - March 6, 2014 Category: Pharmaceuticals Source Type: news

Cervical cancer sufferers to be first to trial Avastin
Trials show Avastin, which is already used in other cancers, gives women almost four months’ extra life. It will be available to patients via the Cancer Drugs Fund. (Source: the Mail online | Health)
Source: the Mail online | Health - March 6, 2014 Category: Consumer Health News Source Type: news

Cash for new cervical cancer drug
Some 500 women in England could benefit as new drug added to approved cancer drugs fundRelated items from OnMedicaNew multi-million pound fund to boost cancer drug developmentInjectable form of Herceptin could simplify breast cancer treatmentNICE rejects use of Avastin for breast cancerNew five-year pricing deal on NHS branded medicines agreed Some expensive cancer drugs could become more widely available (Source: OnMedica Latest News)
Source: OnMedica Latest News - March 6, 2014 Category: UK Health Source Type: news